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Background: Acute myocardial infarction (AMI) in young women represent an extreme phenotype associated with
a higher mortality compared with similarly aged men. Prothrombotic gene variants could play a role as risk factors
for AMI at young age.
Methods: We studied Factor V Leiden, FII G20210A, MTHFR C677T and beta-fibrinogen -455G>A variants by
real-time PCR in 955 young AMI (362 females) and in 698 AMI (245 females) patients. The data were compared to
those obtained in 909 unrelated subjects (458 females) from the general population of the same geographical area
(southern Italy).
Results: In young AMI females, the allelic frequency of either FV Leiden and of FII G20210A was significantly higher
versus the general population (O.R.: 3.67 for FV Leiden and O.R.: 3.84 for FII G20210A; p<0.001). Among AMI patients
we showed only in males that the allelic frequency of the MTHFR C677T variant was significantly higher as
compared to the general population. Such difference was due to a significantly higher frequency in AMI males of
the MTHFR C677T variant homozygous genotype (O.R. 3.05).
Discussion and conclusion: Our data confirm that young AMI in females is a peculiar phenotype with specific risk
factors as the increased plasma procoagulant activity of FV and FII. On the contrary, the homozygous state for the
677T MTHFR variant may cause increased levels of homocysteine and/or an altered folate status and thus an
increased risk for AMI, particularly in males. The knowledge of such risk factors (that may be easily identified by
molecular analysis) may help to improve prevention strategies for acute coronary diseases in specific risk-group
subjects.
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Given its high incidence, morbidity and mortality, acute
myocardial infarction (AMI) is a relevant clinical and so-
cial problem making heart disease a leading killer par-
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distribution, and reproduction in any mediumand cohort studies revealed an excess mortality risk fol-
lowing AMI in young women compared with similarly
aged men [3]. The higher risk may be due to a higher
prevalence of various traditional and emerging risk fac-
tors in this group compared with men. Data on risk fac-
tors for young AMI may help to improve strategies for
its prevention. In a relevant percentage of cases, young
AMI occurs independently of the presence of typical risk
factors such as dyslipidemia, smoking, hypertension, dia-
betes. In such cases, familiarity for AMI is frequently
observed suggesting that genetic predisposition plays a
relevant role [4].
Prothrombotic gene variants were found in genes
involved in haemostasis and its inhibition, leading to atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Number and allelic frequency (%) for prothrombotic gene variants in males and females from the general
population
Group FV Leiden FII G20210A MTHFR C677T Beta Fibrinogen -455G>A
Female subjects 21/870 (2.4%) 22/870 (2.5%) 395/916 (43.1%) 108/744 (14.5%)
Male subjects 21/848 (2.5%) 21/848 (2.5%) 365/902 (40.5%) 78/564 (13.8%)
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variants are: Factor V (FV) Leiden, which causes resist-
ance to protein C; prothrombin (FII) G20210A variant,
that causes a higher plasma level of FII; the C677T vari-
ant of methylene-tetrahydrofolate reductase (MTHFR)
enzyme which impairs the homocysteine pathway
thereby causing higher serum levels of homocysteine
that acts as a trigger for coagulation at endothelial level;
and the -455G>A variant of beta-fibrinogen which
causes increased levels of fibrinogen [5]. Prothrombotic
gene variants are already known to be risk factors for re-
current venous thrombosis [6], particularly in patients
with other predisposing disease [7] whereas there is no
consensus regarding the role of such variants as risk fac-
tors for arterial disorders, including AMI and young
AMI [8-12]. The discordant results reported so far may
reflect heterogeneous selection criteria and the different
number of AMI patients and controls analyzed in differ-
ent studies [13], and the fact that most studies pooled
male and female patients thereby obscuring eventual
gender differences. The different results may also depend
on the variable incidence of prothrombotic variants in
subjects of different ethnic background, and on the fact
that some studies compared the frequency of prothrom-
botic gene variants obtained in AMI patients with that of
control populations of other geographical areas.
The aim of the present study was to evaluate the poten-
tial role of the four prothrombotic gene variants as risk
factors of either young AMI and AMI in female and male
subjects in comparison to a large group of individuals
from the general population of the same geographic area,
whose sex and age distribution corresponded to the ana-
graphic distribution of the population of southern Italy.
Materials and methods
Subjects
We studied: i) 955 young AMI patients (362 females and
593 males), mean age: 38.7 years; and ii) 698 AMITable 2 Number and allelic frequency (%) of prothrombotic g
population
Group A FV Leiden FII G20210A
Female 61/724 (8.4)* 65/724 (9.0)**
Male 41/1186 (3.5) 50/1186 (4.2)
General population 42/1718 (2.4) 43/1718 (2.5)
*Significantly different (p<0.001) versus the general population (O.R.: 3.67; C.I.: 2.45-
** Significantly different (p<0.001) versus the general population (O.R. 3.84; C.I.: 2.59patients (245 females and 453 males), mean age: 69.5
years. All patients were from southern Italy at least from
three generations.
Acute myocardial infarction was diagnosed according
to the Joint ESC/ACCF/AHA/WHF Task Force for the
Redefinition of Myocardial Infarction [14]. AMI patients
had their first episode at an age above 45 years, whereas
young AMI patients had their first episode before the
age of 45 years. All patients were negative for previous
AMI and for other major ischemic diseases such as is-
chemic stroke or lower limb ischemia. Each patient
released informed consent to their blood sample and
clinical data being used for anonymous scientific studies
on genetic susceptibility to AMI. A blood sample was
obtained from each patient during a routine visit.
The data of prothrombotic variants obtained from
AMI and young AMI patients were compared to those
of a group from the general population of southern Italy
constituted by 909 unrelated subjects (458 females and
451 males; mean age: 54 years) from southern Italy up
to the third generation. The sex and age distribution of
this group (see Table 1) matched the anagraphic distri-
bution of subjects in southern Italy. For most of the sub-
jects from the general population, DNA samples were
already available in the bank of biological samples from
the institutions involved in the study, and are currently
used collectively for the study of gene variants associated
with inherited diseases [15,16].
This study was performed according to the ethical
requirements of the institution, and the informed con-
sent was obtained from each individual.
Methods
The DNA for the analysis of prothrombotic gene var-
iants was extracted from leukocytes using a commercial
kit (Nucleon BACC2, Amersham Biosciences, Little
Chalfont, UK). The four prothrombotic gene variants,
i.e., Factor V Leiden, FII G20210A, MTHFR C677T andene variants in young AMI female, male and general
MTHFR C677T Beta Fibrinogen -455 G>A
280/720 (39) 96/714 (13.4)
505/1186 (42.6) 178/1098 (16.2)
760/1818 (41.8) 186/1308 (14.2)
5.49).
-5.70).
Figure 1 Allelic frequency (%) of the FV Leiden and FII
G20210A in young AMI females, males and in female from the
general population.
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lyzed using a specific commercial kit based on real-time
PCR and ligth-cycler analyzer (Roche, Monza, Italy). For
FIIG20210A, MTHFR C677T and -455G>A variant, the
variant alleles were respectively: “A”, “T” and “A”.
Statistics
To compare i) the distribution of allele and genotype
frequencies in the different age groups and sex of con-
trol subjects from the general population and ii) the dis-
tribution of allele and genotype frequencies of the four
gene variants obtained in patients and in control sub-
jects we used the Yates’ chi square test. A p level <0.001
was considered significant.
Results
The three populations of our study resulted in the
Hardy-Weinberg equilibrium for all tested gene variants.
General population
Table 1 reports the data of allelic frequency for the four
prothrombotic variants (FV Leiden, FII G20210A,
MTHFR C677T and -455G>A of beta fibrinogen) in sub-
jects from the general population. No significant differ-
ences were obtained between males and females for any
of the variables. Furthermore, we compared the distribu-
tion of the allelic frequencies for the four variables in
different classes of ages (i.e., < 20 yrs, 20 to 40 yrs, 40 to
60 yrs and > 60 yrs). Again no differences were recorded
(data not shown); thus all subjects from the general
population were pooled together in next comparisons.
Young AMI patients
Table 2 reports the allele frequencies of the four variants
(FV Leiden, FII G20210A, MTHFR C677T and -455G>A
of beta fibrinogen) obtained in male and female with
young AMI. As shown in Figure 1 the allelic frequency
of the FV Leiden was significantly higher (p<0.001) in
young AMI females (8.4%) than in young AMI males(3.5%) and in the general population (2.4%). Similarly,
the allelic frequency of the G20210A variant was signifi-
cantly higher (p<0.001) in young AMI females (9.0%)
than in young AMI males (4.2%) and in the general
population (2.5%, Figure 1). Then, FV Leiden had a odds
ratio for young AMI in females of 3.67 (C.I.: 2.45-5.49),
while FII G20210A had a odds ratio of 3.84 (C.I.: 2.59-
5.70). As shown in the same Table, the allelic frequency
of the two other prothrombotic variants (i.e., the
MTHFR C677T and the -455 A>G beta fibrinogen vari-
ant) did not differ significantly in females with young
AMI compared with young AMI males and with the
general population.
AMI patients
Also, we screened AMI patients for the four prothrom-
botic gene variants. Table 3 reports the data of allele and
genotype frequency obtained in male and female AMI
patients. In male AMI patients, only the allelic frequency
of the MTHFR C677T variant (63.7%) was significantly
different (p<0.001) versus AMI females (47.2%) and ver-
sus the general population (41.8%); the odds ratio was
2.45 (C.I.: 2.07-2.89). The allelic frequency of the three
other variants, i.e., FV Leiden, FII G20210A and
-455G>A variant of beta fibrinogen did not differ signifi-
cantly between AMI patients and the general population.
We next compared the frequency of the homozygous
variant genotypes of MTHFR (C677T) and of beta fi-
brinogen -455G>A in male AMI patients versus AMI
females and versus the general population (Table 3B);
the frequency of the homozygous MTHFR C677T
genotype was significantly higher (p<0.001) in male
AMI patients (39.8%), than in AMI females (26.2%) and
versus the general population (17.8%), the odds ratio
was 3.05 (C.I.: 2.36-3.93).
Discussion
To our knowledge, this is the first study investigating
the possible involvement of the prothrombotic gene var-
iants as risk factors of AMI in different gender and age
subjects. Our data indicate that the FV Leiden and FII
G20201A variants in females represent a risk factors for
young AMI, namely, patients who developed the first
episode of AMI before reach the age of 45 years. The FV
Leiden is associated to a resistance to the inhibitory ef-
fect of protein C that enhances a procoagulant activity,
while the FII G20210A variant causes higher levels and
more pronounced procoagulant activity of FII, both of
which may predispose to ischemic diseases [5]. We
observed a higher frequency of such variants only in
young AMI females and not in young AMI males or in
AMI females, confirming that young AMI females are a
well-defined group of subjects with peculiar risk factors
[1-3]. On the other hand, risk factors for young AMI are
Table 3 Allelic frequency (A) and frequency of homozygous variant patients (B) for prothrombotic gene variants in
AMI female, male and general population
Group A FV Leiden FII G20210A MTHFR C677T Beta Fibrinogen -455G>A
Female 17/490 (3.5) 16/472 (3.4) 220/466 (47.2) 93/470 (19.8)
Male 23/906 (2.5) 25/878 (2.8) 561/880 (63.7)* 141/890 (15.8)
General population B 42/1718 (2.4) 43/1718 (2.5) 760/1818 (41.8) 186/1308 (14.2)
Female 0 0 61/233 (26.2) 17/235 (7.2)
Male 0 0 175/440 (39.8)** 27/445 (6.1)
General population 0 0 162/909 (17.8) 18/654 (2.75)
*Significantly different (p<0.001) versus the general population (O.R.: 2.45; C.I.: 2.07-2.89).
** Significantly different (p<0.001) versus the general population (O.R.: 3.05; C.I.: 2.36-3.93).
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sclerosis burden is less relevant in young AMI, particu-
larly in women [4]. While, genetic factors seem to be
more relevant [4,17,18]. Our data are in accordance with
the results of a large study by Mannucci et al. [9] in which
there was a higher (albeit not significantly different) allelic
frequency of the FII G20210A variant in young AMI than
in controls; however the authors did not analyze the data
in terms of gender, and the group they studied contained
more men than women (1680 men and 210 female). In
the same study, the FV Leiden mutation was significantly
more frequent in young AMI patients.
Furthermore, our data indicate that the C677T
MTHFR variant confers a higher risk for AMI to males.
Such variant is a known risk factor for coronary heart
disease [19], but our study revealed that only male
homozygous subjects for this variant have a higher odds
ratio for AMI. The MTHFR C677T variant causes higher
homocysteine and lower folate levels in serum, and this
is particularly true in homozygous subjects. In this con-
text, it is noteworthy that the mechanism by which high
levels of circulating homocysteine or low levels of folate
may contribute to AMI pathogenesis it is still obscure
[20]. Interestingly, we observed a higher frequency of
MTHFR C677T only in AMI males and not in young
AMI patients. It is conceivable that this variant acts as a
risk factor in older but not in young subjects because
the latter have a better folate intake [21]. The other
three prothrombotic variants we investigated (FV Lei-
den, FII G20201A and -455 G>A in the gene encoding
the beta-fibrinogen) do not seem to contribute to AMI
risk. These data are in partial discordance with previous
studies that implicated these gene variants in AMI, but
in most cases the sample size and the differences be-
tween patients and controls were small. Another study,
in agreement with ours, excluded a major role of these
variants as risk factors for AMI [17] and a large meta-
analysis concluded that prothrombotic gene variants are
only moderately associated with the risk of coronary
diseases [9].Conclusion
AMI is a multifactorial disease due to the combination
of many genetic and environmental risk factors; this is
the first study reporting on a significant association be-
tween some prothrombotic gene variants and the occur-
rence of young AMI in females, confirming the
peculiarity of such phenotype. These data (once con-
firmed in other populations) may contribute to a better
stratification of the genetic AMI risk in different age and
gender subjects and may have implications for the use of
therapies to reverse the prothrombotic phenotype in
high risk patients.
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